Walmart’s Consumer Warning… And Eli Lilly’s Latest Tip Of The Scales 5/21/26

17:49Tim Seymour:But in terms of the longer term plan, Steve, I mean, part of for Workday, it's unleashing all these agents, agents that will help with corporate travel, for instance, doing expenses, all these things that we don't like to do and would love to have an agent do. And that's sort of where it is. The pop, though, we should, you know, just sort of caveat that because there's a 12 percent short interest in the stock. So part of that 10 percent pop, 9 percent pop we're seeing right now is fueled by that. Workday is back to the COVID lows or thereabouts within reason. Do you think we're at the COVID lows for this stock?

18:25I would say no. And you have to look at the SaaS companies through two different lenses. Which ones are the infrastructure plays? And I think ServiceNow and Workday fit into that category. which ones are the ones that could be replaced easily by artificial intelligence. That's front office, back office. So back office are the infrastructure place that I'm talking about. But when you look at it on a chart, you go back, you know, obviously six years on this. Is there any reason why this should be trading at covid lows? I think not. So I would be a buyer of this. March of 2020. Steve's talking about I'm looking at the same thing.

19:05he is. And we did it on big volume and we're bouncing. Listen, you want to play the valuation game. It's even with this move, it's probably trading at 10 and a half, 11 times next year's numbers, which is never a reason to buy these things on the way down. But something people will focus on now that you got a quarter out of the way and it actually looks sort of interesting. So I think there's more left to the subside move in Workday.

19:24Tim Seymour:Coming up even more after our action, the details out of Decker's Ross stores take two and Zoom ahead. But first, Another IPO countdown. Investors gearing up for OpenAI's blockbuster debut. What to expect from the filing and what getting to market first could mean for the AI race. Don't go anywhere. Fast Money is back in two.

19:44This is Fast Money with Melissa Lee right here on CNBC.

19:52Tim Seymour:Is Bitcoin complicated or do people just think it is? For a long time, it felt like something only tech experts or hardcore investors really understood. Between all the headlines, new terminology, and everything people say about it, it can seem harder than it needs to be. But what if getting started with Bitcoin didn't have to feel overwhelming? If you've been curious about Bitcoin but haven't made the jump yet, Cash App makes it easy. You can set up automatic purchases with zero fees or buy larger amounts also with zero fees. Start small or go bigger. It's designed to be simple either way. For a limited time, new customers get$10 added to their balance.

20:30Tim Seymour:Just use code CASHAPP10 when you sign up and, don't forget this part, send at least$5 to a friend in the first two weeks. Terms apply. Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partners. Bitcoin services provided by Block, Inc. Brand. For additional information, see the Bitcoin disclosures at cash.app. slash legal slash podcast. Pandora makes it easy for you to find your favorite music. Discover new artists and genres by selecting any song or album, and we'll make you a personalized station for free. Download on the Apple App Store or Google Play and enjoy the soundtrack to your life.

21:05With Uber's new women preferences, women riders can request a woman driver whenever they want. Like Amy, who's traveling solo in a city she's never been to before. Or Danielle, who works night shifts at the hospital. or Kelly and Jana, who were way overdue for a night out. Because sometimes comfort comes from having another woman with you. Request women drivers with women preferences on Uber. Learn more on the Uber app.

21:38Tim Seymour:Welcome back to Fast Money. The IPO boom about to kick into even higher gear with OpenAI expected to file for its offering. as early as tomorrow. CNBC's Kate Rooney's got the latest. Kate. Hey, Melissa. So OpenAI, from what we're hearing, is preparing to file for an IPO confidentially as soon as tomorrow, looking to go public. From what I'm hearing, as soon as September, this is according to a source familiar with those plans. It would follow the SpaceX listing that you guys have been talking about with its AI business. XAI, I'm also told by sources that rival Anthropic has been getting IPO ready behind the scenes, but no word on exactly when it would file.

22:11Tim Seymour:OpenAI, though, really planting the flag here getting out ahead of what is its biggest competitor, Anthropic, to try to frame its story and some of the financials to Wall Street. We're not going to see the numbers, guys, until the S1 flips. So that would be closer to the listing date, likely in the fall. But we have gotten some breadcrumbs of revenue growth. Of course, these are private companies. But a source tells me OpenAI's first quarter revenue was around$6 billion. That in Q1 was above Anthropic's revenue. The information was first to report this one. But in the second quarter, Anthropic appears to be pulling ahead from what we're hearing, almost$11 billion in revenue for Q2.

22:46Tim Seymour:That would double what it saw in the first quarter and mark its first profitable quarter. It would also top all of sales that the company saw last year. According to a source familiar with those numbers, OpenAI has taken a much more aggressive approach when you look at data center spending and compute, argues that is a strategic moat amid a compute crunch, but it could also mean much larger near-term losses, guys. But we will see. Back over to you. Yep. Kate, thank you. Kate Rooney. Do you want to see Anthropic be a profitable company right now? Or do you want to see it spending for growth?

23:18Melissa Lee:I think, you know, and Kate just said this. I mean, both these companies are compute constrained. Right. And so one of the knocks on Anthropic over the last couple of years is they were not nearly as aggressive as OpenAI was. So, you know, to the point, I mean, OpenAI is losing money hand over fist, but they're also growing revenue at an astonishing rate. I mean, when you think about how much revenue, the tens of billions of dollars these companies have amassed over the last, you know, just couple of years, it's pretty astounding. At some point, it will justify the spend. And these companies that, you know, again, we don't know when it's going to end.

23:48Melissa Lee:We don't know what the demand is going to be. We don't know what the return on investment, you know, by the companies that are going to be using this compute. But the one thing I think is really important, if OpenAI is able to make this transition more towards enterprise, and that's what Anthropic has been doing. It's a more recurring sort of thing. not relying on consumers paying$20 a month and not relying on an ad business that doesn't exist just yet. You know what I mean? So again, that's probably the bull case for OpenAI, if they're able to demonstrate that they're making inroads in the enterprise with this new coding product that they have and taking share away from Anthropic.

24:22Melissa Lee:But this is not going to be a winner take all right now. I mean, there's a lot of folks, there's a lot of runway. We just spent a lot of time talking about ServiceNow and Workday and how poorly positioned than they are, this technology is going to help some of those companies come back from the dead.

24:36Tim Seymour:I agree in terms of the long-term picture. But right now, I mean, in terms of the snapshot going public, it seems like a bigger leap to say that OpenAI will have a meaningful enterprise business right now. Anthropic is so far in advance.

24:49Melissa Lee:Listen, we're going to have three companies that are coming public this year that are probably equal to$5 or$6 trillion in market cap, and all of them are wildly unprofitable. This is not something that we have seen in the S &P 500, or the NASDAQ 100, probably ever. You know what I mean? So these are going to be some of the biggest companies in the indices, and they don't make money. In terms of size, yes. In terms of 20-something years ago, Amazon was a company that everybody was excited about that was not profitable for quite some period of time. And they were given the benefit of the doubt until they weren't, if you recall, because there was a period of time where Amazon went down about 90%.

25:22People forget that. Dan doesn't.

25:23Melissa Lee:Well, the irony also is that AWS was part of the bear story 20 years ago. I mean, people are like, what are they doing spending on this? And now we just talked about this again, really surrounding the trade here. I mean, now this is basically the valuation. The North American retail business is valued at what, Guy? No, I like that. Nothing. Yeah.

25:41Tim Seymour:That was a thing we used to do. But, I mean, it just shows you how fierce the competition is in terms of opening. I really rushed. And we had all those reports, Julie, about the CFO saying that, you know, basically they're not ready. The numbers aren't ready yet to go public. And yet here we are. we're hearing about that filing as soon as tomorrow. It's pretty concerning if you're an investor to hear that you have a CFO that is not ready to publicly file because they're really concerned about the quality of the numbers. And all you have to do is go through the SpaceX S1, which I delightfully did yesterday, to see that these numbers are really not great.

26:18And unlike Amazon, I think what's really different different about this whole scenario is that when we're talking about the build out of telecom, the build out of rails, all of these kind of huge build outs, we were doing it with assets that were not depreciating on a two and three and four year cycle. And that's different in this case. And so I think that's the discomfort that a lot of us have is, you know, they're talking to us about adjusted EBITDA. EBITDA is not relevant when you are spending this much on CapEx just to sustain your business, to say nothing of the margins that you're charging.

26:49So I remain really, really concerned. We really want to see these numbers to get a sense of what the potential can be. We understand that businesses can be unprofitable when they come to market, but there has to be kind of a long-term path and trajectory, and it's really difficult to see that right now.

27:06Tim Seymour:Coming up, turning up the volume on Spotify, the headlines out of the music streamer's Investor Day that has investors tuning in, and why being a superfan could pay off in a big way. You're watching Fast Money live from the Nasdaq market site in Times Square, back right after this.

27:48We'll be right back. Request a woman driver whenever they want. Like Amy, who's traveling solo in a city she's never been to before. Or Danielle, who works night shifts at the hospital. Or Kelly and Jana, who were way overdue for a night out. Because sometimes comfort comes from having another woman with you. Request women drivers with woman preferences on Uber. Learn more on the Uber app. Out on the road, it helps to have a partner like the Love's Rewards app. Download Love's Rewards and get great deals, like a free Love's coffee or fountain drink. Just buy any four, any size, and get the fifth one free.

28:29Love's Rewards, save and earn at every turn. Terms apply, see website for details.

28:33Tim Seymour:Welcome back to Fast Money. Stocks posting some small gains today. The Dow jumping 276 points and closing at a record high. It's first since February. The S &P and Nasdaq both with fractional gains. WTI crude pulling back again today, falling 2%, selling just above$96 a barrel. Shares of Spotify jumping 13%, its best day since February after hosting Its Investor Day. The company announcing a partnership with Universal Music to double down on AI in unveiling new offerings, allowing eligible premium subscribers to reserve concert tickets and an AI tool that generates custom podcasts from user prompts.

29:07Tim Seymour:Shares of Spotify still down more than 20 % over the past year. Some after-hours action, shares of Estee Lauder jumping on a report that cosmetics giant ended a merger, merger talks, I should say, with the Spanish beauty company Puig. The stock fell sharply in March when rumors of a deal hit the market. IMAX also higher after WSJ report that the movie screen company is exploring a sale. Shares are still down 20 percent from their 52-week highs. And some new ads to the S &P Small Cap Index, Universal Technical Institute and Peloton will join the index on May 27th. And more earnings to bring you.

29:42Tim Seymour:Decker's Raw Stores and Zoom, all topping earnings and revenue estimates. Take-Two also jumping after beating revenue expectations. The company adding its Grand Theft Auto 6 video game is still on track for a November release. That was a lot of information. Steve Grasso, what do you want to trade? Yeah, so Raw Stores is one of the obvious ones. They don't have – we had a guest on last week. We discussed what their tailwinds are. They don't have any tariff issues. They're domestic. They get to benefit from the overordering that other corporations do to stay ahead of whatever tariff headwinds that they have.

30:20And then if you look at Spotify, this is a really interesting one. If there's one thing that AI should, in theory, be able to disrupt, it should be Spotify. And if you look at the performance from April up into this recent pop, stock wasn't doing that that well. And there's going to be label renegotiations. Margins probably get compressed. I think you actually sell Spotify off of this, oddly enough.

30:47Melissa Lee:Yeah, I'll take the opposite of that. I mean, if anything, I think they're going to leverage AI. They have been, right? So if they've been using machine learning for years now, we call it AI, right? And there's so many different levers that they can pull as it relates to recommendations, but also, you know, content creation. And then when you think of the integration with some of the deals that they just mentioned today, I mean, I think these are things that are going to be tailwinds, right? Especially when investors have not been too excited about this. If you look at the potential for margin growth, which is what they're guiding to, that's what they spoke to at this investor day.

31:16Melissa Lee:And they also guided towards, you know, a billion users. Half of those are paid. That dwarfs what Apple Music has. So to me, I find this one very interesting. And if Guy was playing Would You Rather, I'd probably go with this over Netflix right now.

31:29Tim Seymour:Interesting. You weren't, though, were you? I can't. But may I say something about Spotify? Quickly, because this is supposed to be a short block. It upsets me. I have my Spotify playlist, like 900 songs, as I mentioned. Yes. And then at the bottom of it has songs like they think that I would like. Yes. Why do they think that? Why do they think I would like a Doobie Brothers song or a Chicago song? Both those bands suck. I don't like either one of them. Well, because you have 900 songs on your playlist, there's no way for AI to determine what you actually like. Clearly. It's too all-encompassing.

31:57Tim Seymour:Thank you. You made my point for me. What, that your list stinks? No, that they can't figure out what I like. Anyway, coming up, Pharma and Focus, The latest trial results on Eli Lilly's next-gen weight loss drug in the stocks making moves after the ASCO data drop. All that when Fast Money returns.

32:20Tim Seymour:Welcome back to Fast Money. Scientific abstracts are out ahead of the American Society of Clinical Oncology's annual meeting, otherwise known as ASCO. It offers an early look on the advances in cancer treatment set to dominate this year's conference. Annika Kim-Constantino joins us now with some of the key readouts. Annika. That's right, Melissa. So we're watching moves in two familiar names. A lot of the major data is being presented next week, but we're still seeing some pops from BioNTech and Merck. So BioNTech is up almost 6 % after mid-stage data on its biospecific antibody drug combined with chemotherapy as a first treatment for patients with a certain type of lung cancer.

32:52Tim Seymour:Meanwhile, Merck is also up 3 % on phase 3 results on a targeted cancer drug combined with Keytruda as a first treatment for patients with another certain type of advanced lung cancer as well. And so that combo reduced the risk of disease progression and death by 65 % compared to Keytruda alone. And so what these two data sets have in common is that these are treatments in the first line setting, so they have the potential to challenge or expand the standard of care here. And we're going to come back to you with any other movers here. All right, Annika, thanks. Annika Kim-Constantino. Well, today's other big health care story, Lilly rising 2 % after giving fresh data on his triple agonist weight loss shot.

33:27Tim Seymour:Over 80 weeks, patients on the highest dose of retitrutide shed 28 % of their body weight. That's an average of 70 pounds. Almost half a patient saw weight loss greater than 30 percent. For more, let's bring in Mizuho Healthcare Specialist, Jared Holtz. Jared, great to have you with us. The expectations were already high on Reditrutide or Triple G. And so I'm wondering, you know, how you think the actual data compared with what was expected. Yeah, I mean, we were all sort of expecting 25 to 30 percent weight loss for this drug, which is obviously very powerful. And that's sort of what we got. So I wasn't shocked by the results.

34:04Again, you know, when we look at these things from a stock perspective, there's been such a hyper focus on on percentage of weight loss. And so the company sort of delivered on expectations for sure.

34:17Tim Seymour:I wanted to ask you about this this note from Bernstein. I know that's probably taboo to ask you, but basically the argument was that, you know, Lilly was going to cream Novo Nordisk because Lilly is a marketing machine and its oral pill will eventually overcome the Wagovi pill that is going to continue. Lilly will continue gaining on the injectable front, et cetera. And I'm wondering how much you agree with that, if at all. Well, I feel like the execution piece of the Lilly versus Novo debate or discussion has sort of already played out. And going forward, it seems like if you're looking at these stories today that Novo is gaining a lot of momentum in the oral market to just come out and say that Lilly is going to be victorious there as well, I think sort of negates a lot of the success that Novo has had early on with the WeGovi pill.

35:17On the injectable side, yes, I think it's clear that Lilly is in the lead and probably will continue to be in the lead for a while. But I don't think there's anything totally new there. I guess my one pushback would be you have over a million patients now on the Wegovi pill, and it's being completely overlooked, again, in my opinion, versus what Lilly's doing. I'm not throwing a curveball at you, but I know you're capable, Jared. This Merck news, which we just heard, seemingly could be not a death knell, but obviously a negative for Summit. Is that move lower that Summit's probably not enjoying right now?

35:53Is that going to be some sort of opportunity down the road? It could be. I mean, the Summit was down a couple of weeks ago because they they've basically not delayed their trial, but they didn't take an interim look. And so we're going to have to see, you know, when that when the final version of that trial reads out what it looks like. I do think this Merck is maybe a small negative for Summit. Again, it's really tough to look at these trials in a vacuum and say it's definitively bad for the other player. We still need to figure out whether this PD-1, VEGF combination is really the real deal.

36:30Tim Seymour:What are some of the other companies you're watching for in terms of big moves, big data dumps? Well, I think the one that the street's really looking forward to the most, and I am as well in part, is Revolution. just given the fact that pancreatic has really taken center stage. I imagine this is going to be the one where investors and the clinical community sort of rally around. And we'll get probably a little bit more durability or duration data out of revolution at this meeting. I think the large cap pharma names are interesting. Obviously, Merck, Roche is going to have some data as well. BioNTech was mentioned previously.

37:07And then there are a couple of small caps like Corpus and BICARA that will have ADC data. Again, probably more incremental versus stuff that is truly novel. But anytime you're dealing with small cap stocks and they introduce something even on the margin, sometimes it's meaningful.

37:24Tim Seymour:All right, Jared, great to see you as always. Thank you, Jared Holtz of Mizuho. In terms of a cap pharma or I mean, which one? This Merck news, and I can't speak intelligently about what this means to Keytruda's patent cliff. But, you know, when you start to use Keytruda with other drugs, that might extend it or give them sort of a new lease on life. So I think Merck is a buy here. Julie, do you see health care as being an area to, you know, so you can like hedge AI in the market? I do. I do like owning health care. I don't like owning this kind of pharma, especially when we're talking about small and mid cap.

38:01You're dependent on one drug and you're dependent on FDA submissions. But companies like a West Pharmaceutical that provide, you know, the components around the drug delivery mechanism, those I'm all for. All right. Grasso. Yeah. So to Guy's point, Merck is up 10 percent. Johnson & Johnson's up to 10 percent. Bristol's up 10 percent. Lilly's down three and Novo's down 13 percent. There's going to be a string of pearls. I know Guy loves that saying approach to the patent cliff and Merck's doing it better than most. I dare say that the market is sort of moving away from the GLP story. And when you look at Revolution, where Jared was talking about with pancreatic cancer, that stock is up 93 percent.

38:51The home player, XBI. Revolution is actually the number one holding, even though it's fragmented, in XBI. And that has outperformed IBB by a large margin. So go with small cap biotech over the names that you all know and hear about every day. All right.

39:09Tim Seymour:Coming up, a major move in quantum companies as the U.S. takes a leap into the space. Who are the grants are going to and how it could help power the group to new heights? Fast Money is back in tune.

39:24Tim Seymour:Welcome back to Fast Money. Quantum stocks surging today after the U.S. government announced two billion dollars in grants to nine firms working within the space. Inflection, D-Wave, Arquit, Global Foundries, all seeing double-digit gains. IBM, which will get a billion dollars in funding, having its best day in over a year, and single-handedly sending the Dow to a record close. Steve, you've been in these names. Yes, I'm in currently IonQ and Inflection. And the IonQ is the I in my Enigma trade, our fast money acronym game. This is something where the government gives you a validation of these companies, changes the complete landscape of the investment community.

40:07Everyone was looking at these being a 10 and 15 year time horizon. That time horizon has brought forward probably two to five and they are making revenue now. Not profitable, but when you look at where the puck is going, I make the analogy of quantum is where AI was back in 2018 with a very strong tailwind current.

40:33Tim Seymour:There's still a long runway out there for quantum to actually materialize into something, you know, that actually works right now. But in terms of the government backing guides proved to be right, invest along with the government. Worked at Intel, worked, obviously, MP Corp, right? So people are going to say, you know what, I'm not going to make the same mistake once, twice, three times. And then again, on back of this, my own, if there's a problem in politics, you know what out of me. But, you know, picking winners and losers in companies, to me, is somewhat problematic. And that's what's going on now.

41:05For any administration. For any administration.

41:08Tim Seymour:Coming up, the CEO of one of this year's CNBC Disruptor 50 standouts joins us next. How iambic therapeutics is shaking up the biotech space when Fast Money returns.

41:21Tim Seymour:Welcome back to Fast Money. CNBC's annual Disruptor 50 list was released earlier this week, highlighting the most promising venture-backed companies innovating and reshaping the economy. Iambic Therapeutics has made the list two years in a row. The biotech company develops medicines using its AI-driven drug discovery platform. For more, CEO and co-founder Tom Miller joins us here on set. Tom, welcome to Fast Money. Thank you. Pleasure to be here. What does AI-driven drug discovery actually mean? I think the basic challenge in drug discovery is to find a new molecule that's going to address a target and ultimately a disease.

41:57And that's a massive search problem. And AI helps us explore that search. And a platform that can turn those AI designs into experimental data extremely rapidly allows us to close the loop and drive forward discovery to make better medicines.

42:10Tim Seymour:So you've actually discovered candidates and you've partnered, So can you walk us through some of the big partnerships that you have so far? So yes and yes. We actually have a wholly owned pipeline that we've demonstrated got to clinic in a third of the industry average pace. So we now are gathering clinical data with AI Discover Drugs in a way that really validates the platform. And you're right. In addition, we've done multiple major partnerships with Lundbeck, with Revolution Medicines, with Takeda, that are using it also in partnership and providing revenue for the company as well. Why is it that it seems like you're so much farther advanced versus some of the bigger pharma companies that want to do this because it seems obvious but seem to be farther behind?

42:52Tim Seymour:And they're actually going elsewhere. They might go shopping. A lot of molecules are being bought in China, for instance. Yeah. The pharma partners have been great collaborators. They've been very interested in what we're doing with those partnerships that I mentioned. And, you know, it involves multiple challenges of not only creating those novel AI technologies, but integrating them in a way that can manufacture data on a effectively weekly timescale that really allows you to retrain the models and drive forward discovery very quickly. A little bit of a sidetrack. So clinical trials cost hundreds of millions of dollars, sometimes billions of dollars.

43:28Correct. Is this a potential predictive model for companies that are going down a road where you could say, hey, we see what you're doing here, but our model suggests it's not going to work? The tools can absolutely be used in that way. And equally, they can be used to design molecules that not only get to clinic, but they can be predicted to succeed through clinic. And we're absolutely doing that.

43:49Tim Seymour:Do you think we'll ever see the day where AI could supplant maybe early phases of clinical trials? I think that we're already seeing that AI is allowing us to avoid many experiments and many dead ends that otherwise would have been the case, which, in fact, drive up the cost of clinical trials through the high probability of failure. And I do expect that with time that we're going to see that cross the boundary from the preclinical to the clinical side. As somebody who regularly develops new drugs and finds new molecules, I'm wondering what your thoughts are on why so many big pharma companies are going to China to buy molecules there as opposed to staying here in the United States.

44:35Tim Seymour:Is the innovation not happening here at a fast enough pace? What's going on? I think there's great science being done the whole world over. And I think with the rise of AI and with the sophistication of China, I just think there's always a rising tide of innovation and sources of potential new medicines. And we compete in that environment. And the timescales and the success that we're able to show is in that environment. So I think that, you know, there's always going to be the need for incredibly challenging new targets and new medicines. And IAMBIC is showing that we can compete in that landscape.

45:12Tim Seymour:Tom, it's great to speak with you. Thanks for coming in from San Diego. We appreciate it. Tom Miller, Iambic Therapeutics. Grasso, what are your thoughts here? Yeah, I mean, the fact that you can do this, I'd be really interested in seeing what was back tested, how it would have changed the environment of the drugs that have already been out there. But it just leads me back to where I constantly keep going to is the smaller biotech firms. You're going to see a bunch of these flood the market with a lot more efficacy than we've seen in the past. So I think it's a really exciting time to be in small cap.

45:50Tim Seymour:Up next, final trades.

45:59Time for the final trade. Julie Beal. I remain skeptical of AI data centers in space, especially cooling them here on Earth. Aon does it pretty well. Stephen. With this grant information that we received to the market today, I think you're going to see inflection get more coverage, higher price targets, and I think it's just the beginning for one.

46:20Melissa Lee:Dan. Yes, Spotify. I like the story here. I like the reframing of the story, the growth story, and some of the new add-ons they got. And for those Spotify fans out there, please follow Guy's first playlist. Miles said I should say that. I apparently have like 130 followers. I should have a lot more.

46:34Tim Seymour:It's not first. It's only. It's only. By the way, the Knicks, a few blocks south of us, play tonight, as you know. What are the chances of you watching the game? Work the game. Okay, very good. Thank you for watching Fast Money. Mad Money with Jim Cramer begins right now.

47:05as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer. Pandora makes it easy for you to find your favorite music. Discover new artists and genres by selecting any song or album, and we'll make you a personalized station for free.

47:33Download on the Apple App Store or Google Play, and enjoy the soundtrack to your life.